Original Research
Published on 12 Sep 2025
A phase 1b randomized, multicenter, dose determination trial of zelpultide alfa (recombinant human surfactant protein D) in preterm neonates at high risk of developing bronchopulmonary dysplasia
in Neonatology
- 2,221 views